InnoStar is proud to present its comprehensive non-clinical pharmacokinetics (PK) platform, dedicated to supporting drug development with reliable and globally compliant DMPK services. Our platform operates under a full life-cycle quality management system aligned with ICH, NMPA, and FDA guidelines, providing end-to-end support from IND to NDA/BLA stages.

Backed by an experienced team and advanced analytical instruments, we have successfully supported IND approvals for a wide range of drug modalities, including:

• Small molecules, peptides, antibodies (mAb, bsAb, nanobodies)
• Fusion proteins, ADCs, cell and gene therapies (CAR-T, stem cells, AAV, oncolytic viruses)
• Nucleic acid drugs and radiopharmaceuticals

Key service offerings include:

• In vitro PK studies (absorption, distribution, metabolism, DDI)
• In vivo PK profiling across multiple sample types and sites
• Radioactive ADME studies (³H/¹⁴C labeling, tissue distribution, micro-PET imaging)
• Advanced instrumentation: LC-MS/MS, high-resolution MS, flow cytometry, PCR, single-cell sequencing, and more

With a track record of supporting over 200 “first-in-class” R&D projects, InnoStar delivers integrated, data-driven solutions to de-risk development and accelerate timelines.

Ready to optimize your drug’s PK profile?